NasdaqGS:CRNXPharmaceuticals
Is Crinetics (CRNX) Using Brazil’s PALSONIFY Filing To Cement Its Global Endocrine Leadership?
Earlier this week, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY (paltusotine), an oral somatostatin receptor type 2 agonist for treating adult acromegaly, supported by data from 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints.
This move extends PALSONIFY’s global reach beyond its existing US approval and recent positive European CHMP opinion, underscoring Crinetics’ push to position...